-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FY2023 Earnings Estimate for Eledon Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:ELDN)
FY2023 Earnings Estimate for Eledon Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:ELDN)
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink upped their FY2023 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Tuesday, January 10th. SVB Leerink analyst T. Smith now forecasts that the company will earn ($1.80) per share for the year, up from their prior forecast of ($2.00). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($2.61) per share. SVB Leerink also issued estimates for Eledon Pharmaceuticals' FY2024 earnings at ($1.87) EPS, FY2025 earnings at ($2.08) EPS and FY2026 earnings at ($1.97) EPS.
Get Eledon Pharmaceuticals alerts:Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.05).
Separately, HC Wainwright reissued a "buy" rating on shares of Eledon Pharmaceuticals in a report on Thursday, December 15th.Eledon Pharmaceuticals Stock Performance
Shares of ELDN opened at $2.87 on Thursday. The stock's 50-day simple moving average is $2.50 and its 200 day simple moving average is $2.81. The stock has a market capitalization of $39.41 million, a price-to-earnings ratio of -1.08 and a beta of 1.81. Eledon Pharmaceuticals has a 52-week low of $2.03 and a 52-week high of $5.14.
Institutional Trading of Eledon Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in ELDN. CM Management LLC increased its stake in Eledon Pharmaceuticals by 8.9% in the 3rd quarter. CM Management LLC now owns 245,000 shares of the company's stock worth $676,000 after acquiring an additional 20,000 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth about $50,000. Renaissance Technologies LLC increased its stake in Eledon Pharmaceuticals by 74.2% in the 2nd quarter. Renaissance Technologies LLC now owns 32,173 shares of the company's stock worth $79,000 after acquiring an additional 13,700 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in Eledon Pharmaceuticals by 13.2% in the 3rd quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock worth $241,000 after acquiring an additional 10,186 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Eledon Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 679,243 shares of the company's stock worth $2,676,000 after acquiring an additional 9,543 shares during the last quarter. Hedge funds and other institutional investors own 45.59% of the company's stock.
Eledon Pharmaceuticals Company Profile
(Get Rating)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
See Also
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- Optimism About Global Demand For Metals Boosts BHP, Other Miners
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Eledon PharmPharmticals,Inc.(纳斯达克代码:ELDN-GET Rating)-在1月10日周二发布的一份研究报告中,SVB Leerink的研究分析师上调了对Eledon PharmPharmticals股票2023财年每股收益的预期。SVB Leerink分析师T·史密斯现在预测,该公司今年的每股收益将为1.80美元,高于此前预测的2.00美元。对Eledon PharmPharmticals目前全年收益的普遍预期为每股2.61美元。SVB Leerink还发布了对Eledon PharmPharmticals 2024财年每股收益(1.87美元)、2025财年每股收益(2.08美元)和2026财年每股收益(1.97美元)的预期。
到达伊莱顿制药公司警报:纳斯达克(Eledon PharmPharmticals)最近一次发布季度收益报告是在11月14日(星期一)。该公司公布该季度每股收益为0.73美元,低于分析师普遍预期的每股收益(0.68美元)和每股收益(0.05美元)。
另外,在12月15日星期四的一份报告中,HC Wainwright重新发布了对Eledon PharmPharmticals股票的“买入”评级。伊利登制药类股表现
周四,ELDN的股价开盘报2.87美元。该股的50日简单移动均线切入位在2.50美元,200日简单移动均线切入位在2.81美元。该股市值为3,941万美元,市盈率为-1.08,贝塔系数为1.81。Eledon PharmPharmticals的52周低点为2.03美元,52周高位为5.14美元。
伊利登制药的制度性交易
一些机构投资者最近增持或减持了ELDN的股份。CM Management LLC在第三季度增持了8.9%的Eledon PharmPharmticals股份。CM Management LLC在上个季度额外收购了20,000股后,现在拥有245,000股该公司股票,价值676,000美元。Dimension Fund Advisors LP在第三季度购买了Eledon PharmPharmticals的一个新头寸,价值约5万美元。复兴科技有限责任公司在第二季度增持了74.2%的Eledon PharmPharmticals股份。复兴科技有限责任公司在上个季度增持了13,700股后,现在持有32,173股该公司股票,价值79,000美元。Ensign Peak Advisors Inc.在第三季度增持了13.2%的Eledon PharmPharmticals股份。Ensign Peak Advisors Inc.在上个季度额外收购了10,186股后,现在拥有87,286股该公司股票,价值241,000美元。最后,先锋集团在第一季度增持了1.4%的Eledon PharmPharmticals股份。先锋集团目前持有679,243股该公司股票,价值2,676,000美元,上一季度又购入了9,543股。对冲基金和其他机构投资者持有该公司45.59%的股票。
伊利登制药公司简介
(获取评级)
Eledon PharmPharmticals,Inc.是一家临床阶段的生物制药公司,专注于为患有自身免疫性疾病和肌萎缩侧索硬化症(ALS)并需要器官或细胞移植的患者开发药物。它的主要候选产品包括AT-1501,一种人源化的针对CD40配体的单抗,是一种表达在人类免疫系统T细胞表面的分子,目前正处于治疗ALS的2a期临床试验,以及胰岛细胞移植治疗1型糖尿病的2期临床试验。
另请参阅
- 免费获取StockNews.com关于Eledon制药的研究报告(ELDN)
- 对全球金属需求的乐观情绪提振必和必拓等矿商
- 埃克森美孚预计收益和现金流将增长
- 索伦托治疗公司,Scilex:2只热门制药股在移动
- 阿里巴巴大复苏要开始了吗?
- KB Home,房屋建筑类股下跌的另一个原因
接受《Eledon PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Eledon PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧